Press Releases for VPHM

Press Releases
The Fortune Financial Global Market Perspective Review on Schnitzer Steel Industries Inc., ViroPharma Inc., T. Rowe Price Group Inc., Cirrus Logic Inc., Veeco Instruments Inc. and Teton Energy Corp.
BenchmarkJournal.Com Free Analyst Review for OCNF, TSFG, PBCT, VPHM, WFMI and VALE
ViroPharma Announces Initiation Of Non-Toxigenic Clostridium Difficile Phase 1 Program
ViroPharma Announces Support by Advisory Committee of The Office of Generic Drugs Proposed Guidelines for Developing Generic Versions of Oral Vancomycin Hydorchloride
StockPreacher.com Issues Trading Outlook for ViroPharma Inc.
ViroPharma Incorporated Reports Second Quarter 2009 Financial Results
ViroPharma to Release 2009 Second Quarter Financial Results on July 29, 2009
ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors
ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema
ViroPharma to Present at Two June Healthcare Conferences
ViroPharma Announces Meeting of FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology on Bioequivalence Recommendations for Oral Vancomycin Hydrochloride Products
Scientific Data Relating to Cinryze(TM) Presented at 6th Annual C1 Inhibitor Deficiency Workshop
ViroPharma Incorporated Honored by the National Organization for Rare Disorders
ViroPharma to Present at Two May Healthcare Conferences
ViroPharma Incorporated Reports First Quarter 2009 Financial Results
ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
TheFortuneFinancial.Com Initializes Free Analyst Research on VPHM, DNDN, BEAV and VRTX
ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
ViroPharma to Present at the Cowen & Company 29th Annual Healthcare Conference
ViroPharma to Host Investor 'Teach-In' Educational Symposium on Hereditary Angioedema
Zacks Analyst Blog Highlights: ViroPharma, Inc., TOTAL S.A., ReneSola Ltd., AFLAC and Vale Do Rio Doce
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
Zacks Analyst Blog Highlights: Ctrip.Com International, ViroPharma, Internap Network Services Corporation, Allergan, Inc. And Comstock Resources.
ViroPharma to Release 2008 Fourth Quarter and Full Year Financial Results on February 24, 2009
Wall Street News Alert: Movers &Amp; Shakers for Wednesday's Stock Market! February 11, 2009
Zacks Analyst Blog Highlights: Sanderson Farms, ViroPharma, Allion Healthcare Inc., Nordstrom Inc. And Developers Diversified.
Zacks Bull & Bear of the Day Highlights: Sohu.Com, Alkermes, ViroPharma, Sanderson Farms and Nordstrom
ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
Emerald Asset Management Holds Annual Investment Forum
FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference
ViroPharma Files FOIA Complaint Seeking Administrative Record for Vancocin(R)
ViroPharma Announces Changes to Board of Directors
ViroPharma Provides Update on Vancocin(R)
ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema
ViroPharma To Present At The 20th Annual Piper Jaffray Healthcare Conference
ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
ViroPharma to Present at Three November Healthcare Conferences
ViroPharma to Discuss Commercialization and Launch of Cinryze(TM) on November 5, 2008
ViroPharma Incorporated Reports Third Quarter 2008 Financial Results
ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
ViroPharma to Present at Three October Healthcare Conferences
ViroPharma and Lev Receive Hart-Scott-Rodino Clearance from the Federal Trade Commission
ViroPharma and Lev Receive Hart-Scott-Rodino Clearance from The Federal Trade Commission
ViroPharma to Present at Three September Healthcare Conferences
ViroPharma Incorporated Reports Second Quarter 2008 Financial Results
ViroPharma to Acquire Lev Pharmacueticals
ViroPharma To Acquire Lev Pharmaceuticals
ViroPharma to Release 2008 Second Quarter Financial Results on July 30, 2008
Viropharma Comments On Upcoming FDA Advisory Committee Meeting
ViroPharma to Present at Two Upcoming Healthcare Conferences
New Publication of Phase 2 Data Shows Maribavir Markedly Reduced the Rate of Cytomegalovirus Infection and Disease in Bone Marrow Transplant Patients
ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
ViroPharma to Present at the Seventh Annual JMP Securities Research Conference - Jun 2 2008 2:12AM
ViroPharma Incorporated Reports First Quarter 2008 Financial Results
ViroPharma Announces Discontinuation of HCV-796 Development
ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008